Home LiteratureArticle Details
PMID: 29675018 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.

Frontiers in immunology ·Vol. 9 ·2018-00-00 ·Pages 527

Albini A, Bruno A, Noonan DM, Mortara L

Abstract

The critical role of angiogenesis in promoting tumor growth and metastasis is strongly established. However, tumors show considerable variation in angiogenic characteristics and in their sensitivity to antiangiogenic therapy. Tumor angiogenesis involves not only cancer cells but also various tumor-associated leukocytes (TALs) and stromal cells. TALs produce chemokines, cytokines, proteases, structural proteins, and microvescicles. Vascular endothelial growth factor (VEGF) and inflammatory chemokines are not only major proangiogenic factors but are also immune modulators, which increase angiogenesis and lead to immune suppression. In our review, we discuss the regulation of angiogenesis by innate immune cells in the tumor microenvironment, specific features, and roles of major players: macrophages, neutrophils, myeloid-derived suppressor and dendritic cells, mast cells, γδT cells, innate lymphoid cells, and natural killer cells. Anti-VEGF or anti-inflammatory drugs could balance an immunosuppressive microenvironment to an immune permissive one. Anti-VEGF as well as anti-inflammatory drugs could therefore represent partners for combinations with immune checkpoint inhibitors, enhancing the effects of immune therapy.

Keywords
angiogenesis chemoprevention immune cells immunotherapy tumor microenvironment
MeSH Terms
Animals Dendritic Cells/immunology Humans Immunity, Innate Immunotherapy Lymphocytes/immunology Macrophages/immunology Mast Cells/immunology Neoplasms/immunology,pathology,therapy Neovascularization, Pathologic/immunology Tumor Microenvironment/immunology
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Albini Adriana
Scientific and Technology Pole, IRCCS MultiMedica, Milano, Italy. | Department of Medicine and Surgery, University Milano-Bicocca, Monza, Italy.
Bruno Antonino
Scientific and Technology Pole, IRCCS MultiMedica, Milano, Italy.
Noonan Douglas M
Scientific and Technology Pole, IRCCS MultiMedica, Milano, Italy. | Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Mortara Lorenzo
Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
References (261)
261 references, click to expand
  1. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A.
    J Immunol. 2004 Apr 15;172(8):5034-40 PMID: 15067085
  2. Targeting natural killer cells in cancer immunotherapy.
    Nat Immunol. 2016 Aug 19;17 (9):1025-36 PMID: 27540992
  3. CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.
    PLoS One. 2016 Feb 26;11(2):e0149600 PMID: 26918785
  4. Microenvironmental regulation of metastasis.
    Nat Rev Cancer. 2009 Apr;9(4):239-52 PMID: 19279573
  5. Immunosuppressive mechanisms of regulatory dendritic cells in cancer.
    Cancer Microenviron. 2013 Aug;6(2):159-67 PMID: 23749739
  6. Neutralizing tumor-promoting chronic inflammation: a magic bullet?
    Science. 2013 Jan 18;339(6117):286-91 PMID: 23329041
  7. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia.
    Immunol Cell Biol. 2010 Feb;88(2):165-71 PMID: 19841638
  8. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice.
    Blood. 2012 Mar 29;119(13):3164-75 PMID: 22327225
  9. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.
    J Clin Invest. 2008 Oct;118(10):3367-77 PMID: 18776941
  10. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.
    Oncotarget. 2017 Jul 18;8(29):48436-48452 PMID: 28467800
  11. Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis.
    Nat Commun. 2017 Nov 17;8(1):1597 PMID: 29150606
  12. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
    J Exp Med. 2005 Oct 3;202(7):919-29 PMID: 16186184
  13. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  14. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer.
    Pancreas. 2002 Mar;24(2):169-78 PMID: 11854622
  15. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression.
    Cancer Res. 2000 Oct 15;60(20):5857-61 PMID: 11059783
  16. The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice.
    Inflammopharmacology. 2014 Dec;22(6):341-9 PMID: 24715223
  17. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils.
    J Immunol. 2002 Jun 1;168(11):5798-804 PMID: 12023382
  18. Innate lymphoid cells: emerging insights in development, lineage relationships, and function.
    Annu Rev Immunol. 2012;30:647-75 PMID: 22224763
  19. The Basis of Oncoimmunology.
    Cell. 2016 Mar 10;164(6):1233-1247 PMID: 26967289
  20. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.
    J Clin Oncol. 2005 Dec 10;23(35):8959-67 PMID: 16219934
  21. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
    Cancer Immunol Res. 2015 Apr;3(4):399-411 PMID: 25678581
  22. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.
    Cancer Cell. 2016 Apr 11;29(4):587-601 PMID: 27070705
  23. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.
    Sci Rep. 2015 Nov 03;5:16053 PMID: 26524953
  24. Paradoxic effects of metformin on endothelial cells and angiogenesis.
    Carcinogenesis. 2014 May;35(5):1055-66 PMID: 24419232
  25. Therapeutic effects of liposomal adriamycin in combination with tumor necrosis factor-alpha.
    J Surg Oncol. 1992 Jan;49(1):20-4 PMID: 1548876
  26. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
    Sci Transl Med. 2017 Apr 12;9(385):null PMID: 28404866
  27. The triterpenoid CDDO-imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer.
    Carcinogenesis. 2016 Dec;37(12 ):1170-1179 PMID: 27659181
  28. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
    Int J Surg Pathol. 2015 Dec;23(8):629-37 PMID: 25911567
  29. IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma.
    Sci Rep. 2016 Nov 07;6:36551 PMID: 27819281
  30. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
    J Clin Invest. 2015 Sep;125(9):3356-64 PMID: 26168215
  31. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.
    Int J Cancer. 2016 Apr 15;138(8):1982-93 PMID: 26619320
  32. Control of the immune response by pro-angiogenic factors.
    Front Oncol. 2014 Apr 02;4:70 PMID: 24765614
  33. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
    Eur J Immunol. 2010 Jul;40(7):1927-37 PMID: 20397212
  34. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
    Cell. 2014 Feb 13;156(4):744-58 PMID: 24529377
  35. Killers become builders during pregnancy.
    Nat Med. 2006 Sep;12(9):991-2 PMID: 16960566
  36. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface.
    Nat Med. 2006 Sep;12(9):1065-74 PMID: 16892062
  37. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.
    Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8 PMID: 16891410
  38. Decidualization and angiogenesis in early pregnancy: unravelling the functions of DC and NK cells.
    J Reprod Immunol. 2011 Mar;88(2):86-92 PMID: 21227511
  39. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.
    Cell. 2015 Sep 10;162(6):1257-70 PMID: 26343581
  40. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis.
    Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20262-7 PMID: 18077379
  41. Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells.
    Cancer Res Treat. 2014 Jul;46(3):297-306 PMID: 25038765
  42. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies.
    Cancer. 2007 Nov 1;110(9):2007-11 PMID: 17823911
  43. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer.
    Clin Cancer Res. 2007 Mar 1;13(5):1472-9 PMID: 17332291
  44. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.
    Cancer Sci. 2010 Nov;101(11):2384-90 PMID: 20825419
  45. M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma.
    Med Oncol. 2014 Aug;31(8):127 PMID: 25034365
  46. IL-17-Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin.
    J Immunol. 2017 Nov 1;199(9):3129-3136 PMID: 28972090
  47. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis.
    Cancer Immunol Res. 2016 Feb;4(2):83-91 PMID: 26839309
  48. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Clin Cancer Res. 2016 Apr 15;22(8):1845-55 PMID: 27084738
  49. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.
    Nat Commun. 2015 Sep 23;6:8280 PMID: 26395069
  50. Macrophage polarization in pathology.
    Cell Mol Life Sci. 2015 Nov;72(21):4111-26 PMID: 26210152
  51. When killers become helpers.
    Trends Immunol. 2007 May;28(5):201-6 PMID: 17403615
  52. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
    J Exp Med. 2015 Feb 9;212(2):139-48 PMID: 25601652
  53. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis.
    PLoS One. 2012;7(1):e30806 PMID: 22295111
  54. Are Mast Cells MASTers in Cancer?
    Front Immunol. 2017 Apr 12;8:424 PMID: 28446910
  55. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.
    Neoplasia. 2013 Feb;15(2):133-42 PMID: 23441128
  56. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis.
    Mediators Inflamm. 2014;2014:623759 PMID: 25110397
  57. Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention.
    Cancer Treat Res. 2014;159:401-26 PMID: 24114493
  58. IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients.
    Int J Cancer. 2016 Aug 15;139(4):869-81 PMID: 27062572
  59. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  60. History of myeloid-derived suppressor cells.
    Nat Rev Cancer. 2013 Oct;13(10 ):739-52 PMID: 24060865
  61. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
    Science. 2018 Jan 5;359(6371):91-97 PMID: 29097494
  62. Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology.
    J Leukoc Biol. 2017 Aug;102(2):325-334 PMID: 28223316
  63. Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
    Cancer Immunol Res. 2017 Jun;5(6):446-454 PMID: 28473314
  64. Innate lymphoid cells involve in tumorigenesis.
    Int J Cancer. 2016 Jan 1;138(1):22-9 PMID: 25604320
  65. Liposomal TriCurin, A Synergistic Combination of Curcumin, Epicatechin Gallate and Resveratrol, Repolarizes Tumor-Associated Microglia/Macrophages, and Eliminates Glioblastoma (GBM) and GBM Stem Cells.
    Molecules. 2018 Jan 18;23 (1):null PMID: 29346317
  66. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis.
    Front Physiol. 2014 Mar 05;5:75 PMID: 24634660
  67. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
    J Immunol. 2007 Mar 1;178(5):2883-92 PMID: 17312132
  68. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Cancer Cell. 2016 Jun 13;29(6):832-845 PMID: 27265504
  69. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.
    Pharmacol Ther. 2016 Feb;158:24-40 PMID: 26617219
  70. Altered macrophage differentiation and immune dysfunction in tumor development.
    J Clin Invest. 2007 May;117(5):1155-66 PMID: 17476345
  71. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
    Science. 2018 Jan 5;359(6371):97-103 PMID: 29097493
  72. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors.
    J Immunol. 2013 Apr 15;190(8):3939-48 PMID: 23487420
  73. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S.
    Nat Cell Biol. 2014 Sep;16(9):876-88 PMID: 25086747
  74. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages.
    J Exp Med. 2008 Jul 7;205(7):1673-85 PMID: 18559453
  75. New insights into the multidimensional concept of macrophage ontogeny, activation and function.
    Nat Immunol. 2016 Jan;17(1):34-40 PMID: 26681460
  76. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.
    J Clin Invest. 2015 Sep;125(9):3365-76 PMID: 26325033
  77. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model.
    J Clin Invest. 2010 Apr;120(4):1151-64 PMID: 20237412
  78. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.
    Oncoimmunology. 2017 Feb 7;6(2):e1267892 PMID: 28344878
  79. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Curr Treat Options Oncol. 2018 Jan 24;19(1):6 PMID: 29368125
  80. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
    Nat Med. 2013 Oct;19(10):1264-72 PMID: 24056773
  81. Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.
    Cell. 2016 Jan 28;164(3):365-77 PMID: 26806130
  82. Tumor-associated macrophages: from mechanisms to therapy.
    Immunity. 2014 Jul 17;41(1):49-61 PMID: 25035953
  83. Tumour-associated macrophages as treatment targets in oncology.
    Nat Rev Clin Oncol. 2017 Jul;14 (7):399-416 PMID: 28117416
  84. NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
    J Immunol Res. 2016;2016:4684268 PMID: 27294158
  85. TGF-β affects development and differentiation of human natural killer cell subsets.
    Eur J Immunol. 2010 Aug;40(8):2289-95 PMID: 20540115
  86. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
    Nature. 2016 Nov 17;539(7629):443-447 PMID: 27828943
  87. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.
    BMC Cancer. 2015 Mar 06;15:101 PMID: 25884667
  88. Human innate lymphoid cells.
    Blood. 2014 Jul 31;124(5):700-9 PMID: 24778151
  89. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2-dependent angiogenesis in mice.
    Hepatology. 2017 Jun;65(6):1920-1935 PMID: 28133764
  90. Innate Lymphoid Cells in Tumor Immunity.
    Biomedicines. 2016 Feb 25;4(1): PMID: 28536374
  91. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.
    Cancer Discov. 2015 Jan;5(1):35-42 PMID: 25312016
  92. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis.
    Eur J Pharmacol. 2016 May 5;778:146-51 PMID: 25941082
  93. Plasticity in mast cell responses during bacterial infections.
    Curr Opin Microbiol. 2012 Feb;15(1):78-84 PMID: 22055570
  94. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells.
    Nat Immunol. 2013 Jun;14(6):564-73 PMID: 23603794
  95. Hypoxia-Inducible Factors: Master Regulators of Cancer Progression.
    Trends Cancer. 2016 Dec;2(12 ):758-770 PMID: 28741521
  96. Mast cells positive to tryptase and tumour-associated macrophages correlate with angiogenesis in locally advanced colorectal cancer patients undergone to surgery.
    Expert Opin Ther Targets. 2016;20(5):533-40 PMID: 26914851
  97. Tumor dormancy and the angiogenic switch: possible implications of bone marrow- derived cells.
    Curr Pharm Des. 2014;20(30):4920-33 PMID: 24283950
  98. The 'T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells.
    Int Immunol. 2011 Jul;23(7):427-31 PMID: 21665959
  99. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  100. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.
    Nat Immunol. 2017 Sep;18(9):1004-1015 PMID: 28759001
  101. STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.
    Cancer Discov. 2016 Apr;6(4):414-29 PMID: 26873347
  102. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
    Cancer Immunol Res. 2015 Nov;3(11):1236-47 PMID: 26025381
  103. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy.
    Cancer Res. 2015 Sep 1;75(17):3479-91 PMID: 26269531
  104. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
  105. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
    Cancer Immunol Immunother. 2017 Aug;66(8):969-977 PMID: 28214928
  106. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death.
    Cancer Res. 2003 Mar 15;63(6):1405-12 PMID: 12649206
  107. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity.
    Nature. 2017 Nov 2;551(7678):110-114 PMID: 29072292
  108. Neutrophils as active regulators of the immune system in the tumor microenvironment.
    J Leukoc Biol. 2017 Aug;102(2):343-349 PMID: 28264904
  109. Dendritic cells in cancer: the role revisited.
    Curr Opin Immunol. 2017 Apr;45:43-51 PMID: 28192720
  110. Immunomonitoring and prognostic relevance of neutrophils in clinical trials.
    Semin Cancer Biol. 2013 Jun;23(3):200-7 PMID: 23403174
  111. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
    Cancer Res. 2013 May 1;73(9):2782-94 PMID: 23418320
  112. The effects of metformin on gut microbiota and the immune system as research frontiers.
    Diabetologia. 2017 Sep;60(9):1662-1667 PMID: 28770326
  113. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer.
    Technol Cancer Res Treat. 2013 Jun;12(3):259-67 PMID: 23289476
  114. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis.
    J Clin Invest. 2013 Jul 1;:null PMID: 23863628
  115. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.
    Front Immunol. 2016 Oct 03;7:407 PMID: 27752258
  116. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
    Cancer Cell. 2014 Jun 16;25(6):846-59 PMID: 24898549
  117. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.
    Nat Cell Biol. 2015 Jun;17(6):816-26 PMID: 25985394
  118. Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils.
    Front Immunol. 2017 Apr 19;8:443 PMID: 28458672
  119. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.
    J Clin Invest. 2014 Dec;124(12):5466-80 PMID: 25384214
  120. Tumor associated regulatory dendritic cells.
    Semin Cancer Biol. 2012 Aug;22(4):298-306 PMID: 22414911
  121. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma.
    J Hepatol. 2011 May;54(5):948-55 PMID: 21145847
  122. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
    Cancer Res. 2013 May 15;73(10):2943-8 PMID: 23440426
  123. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy.
    Biomed Res Int. 2014;2014:154702 PMID: 25295247
  124. Orchestration of angiogenesis by immune cells.
    Front Oncol. 2014 Jul 02;4:131 PMID: 25072019
  125. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
    Neoplasia. 2011 Jan;13(1):23-30 PMID: 21245937
  126. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Science. 2011 Mar 25;331(6024):1612-6 PMID: 21436454
  127. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
    Cancer Cell. 2009 Sep 8;16(3):183-94 PMID: 19732719
  128. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
    Cancer Res. 2010 Aug 1;70(15):6171-80 PMID: 20631075
  129. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis.
    Biomed Res Int. 2015;2015:142359 PMID: 26146612
  130. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017 Jan;66(1):157-167 PMID: 26452628
  131. Cancer Prevention and Interception: A New Era for Chemopreventive Approaches.
    Clin Cancer Res. 2016 Sep 1;22(17 ):4322-7 PMID: 27220959
  132. PPARalpha deficiency in inflammatory cells suppresses tumor growth.
    PLoS One. 2007 Feb 28;2(2):e260 PMID: 17327920
  133. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
    Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6 PMID: 23045683
  134. Targeted Therapy and Immunosuppression in the Tumor Microenvironment.
    Trends Cancer. 2017 Jan;3(1):19-27 PMID: 28718424
  135. Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
    Nature. 2007 Dec 6;450(7171):825-31 PMID: 18064003
  136. Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms.
    Life Sci. 2013 Feb 7;92(2):101-7 PMID: 23178150
  137. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.
    Endocr Relat Cancer. 2008 Dec;15(4):1069-74 PMID: 18719091
  138. Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.
    Clin Ther. 2016 Feb;38(2):297-301 PMID: 26740291
  139. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Trends Immunol. 2016 Mar;37(3):208-220 PMID: 26858199
  140. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
    Sci Rep. 2016 Jan 05;6:18673 PMID: 26728433
  141. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.
    Breast Cancer Res. 2015 Mar 27;17:45 PMID: 25882816
  142. T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1.
    Eur J Immunol. 2018 Feb 9;:null PMID: 29424438
  143. On the cytokines produced by human neutrophils in tumors.
    Semin Cancer Biol. 2013 Jun;23(3):159-70 PMID: 23410636
  144. Human innate lymphoid cells.
    J Allergy Clin Immunol. 2016 Nov;138(5):1265-1276 PMID: 27677386
  145. Macrophage activation and polarization: nomenclature and experimental guidelines.
    Immunity. 2014 Jul 17;41(1):14-20 PMID: 25035950
  146. Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→︀AKT→︀GSK3β→︀AM signaling.
    Oncogene. 2017 May 18;36(20):2879-2888 PMID: 28114284
  147. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
    J Natl Cancer Inst. 2010 Jan 6;102(1):14-25 PMID: 20007921
  148. Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
    PLoS One. 2017 Apr 14;12 (4):e0175712 PMID: 28410380
  149. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.
    Immunity. 2016 Feb 16;44(2):303-15 PMID: 26885857
  150. A beneficial role for immunoglobulin E in host defense against honeybee venom.
    Immunity. 2013 Nov 14;39(5):963-75 PMID: 24210352
  151. The role of myeloid cells in the promotion of tumour angiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):618-31 PMID: 18633355
  152. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.
    Front Immunol. 2013 Dec 25;4:490 PMID: 24400010
  153. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis.
    Genes Dev. 1999 Jun 1;13(11):1382-97 PMID: 10364156
  154. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity.
    Immunity. 2013 Nov 14;39(5):976-85 PMID: 24210353
  155. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.
    J Exp Med. 2012 Mar 12;209(3):495-506 PMID: 22351930
  156. Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model.
    Oncol Rep. 2018 Jan;39(1):280-288 PMID: 29138867
  157. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization.
    BMC Cancer. 2013 Sep 17;13:421 PMID: 24044575
  158. The impact of the immune system on tumor: angiogenesis and vascular remodeling.
    Front Oncol. 2014 Apr 08;4:69 PMID: 24782982
  159. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth.
    Semin Cancer Biol. 2013 Jun;23(3):149-58 PMID: 23410638
  160. The AKT/NF-κB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration.
    Biochem Pharmacol. 2012 Jun 15;83(12):1634-42 PMID: 22445931
  161. Mast cells contribute to vasculogenic mimicry in multiple myeloma.
    Stem Cells Dev. 2008 Feb;17(1):19-22 PMID: 18205547
  162. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.
    Br J Cancer. 1998 Jun;77(12):2246-51 PMID: 9649140
  163. Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.
    Clin Exp Immunol. 2018 Apr;192(1):54-67 PMID: 29235095
  164. Tumor-associated macrophages: implications in cancer immunotherapy.
    Immunotherapy. 2017 Mar;9(3):289-302 PMID: 28231720
  165. Differential macrophage programming in the tumor microenvironment.
    Trends Immunol. 2012 Mar;33(3):119-26 PMID: 22277903
  166. Metabolic regulation of suppressive myeloid cells in cancer.
    Cytokine Growth Factor Rev. 2017 Jun;35:27-35 PMID: 28499577
  167. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells.
    Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3378-83 PMID: 17360654
  168. Effect of tumor cells and tumor microenvironment on NK-cell function.
    Eur J Immunol. 2014 Jun;44(6):1582-92 PMID: 24777896
  169. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease.
    Int J Cancer. 2011 Nov 1;129(9):2183-93 PMID: 21190185
  170. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
    J Clin Oncol. 2017 Jun 1;35(16):1836-1844 PMID: 28406723
  171. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism.
    Mol Nutr Food Res. 2005 Sep;49(9):844-50 PMID: 16144030
  172. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
    Clin Cancer Res. 2013 Nov 15;19(22):6286-95 PMID: 23983255
  173. Role of macrophage targeting in the antitumor activity of trabectedin.
    Cancer Cell. 2013 Feb 11;23 (2):249-62 PMID: 23410977
  174. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides.
    J Immunol. 2012 Jan 1;188(1):345-57 PMID: 22140255
  175. Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?
    Curr Opin Pharmacol. 2017 Aug;35:66-74 PMID: 28623714
  176. Neutrophil recruitment and function in health and inflammation.
    Nat Rev Immunol. 2013 Mar;13(3):159-75 PMID: 23435331
  177. Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.
    Mol Cancer Ther. 2017 Feb;16(2):365-375 PMID: 27980106
  178. Markers and function of human NK cells in normal and pathological conditions.
    Cytometry B Clin Cytom. 2017 Mar;92 (2):100-114 PMID: 28054442
  179. The parallel lives of angiogenesis and immunosuppression: cancer and other tales.
    Nat Rev Immunol. 2011 Sep 23;11(10 ):702-11 PMID: 21941296
  180. Lipid accumulation and dendritic cell dysfunction in cancer.
    Nat Med. 2010 Aug;16(8):880-6 PMID: 20622859
  181. The Yin and Yang of Innate Lymphoid Cells in Cancer.
    Immunol Lett. 2016 Nov;179:29-35 PMID: 27296768
  182. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis.
    Cytokine. 2017 Jan;89:34-44 PMID: 26883678
  183. The Jekyll and Hyde story of IL17-Producing γδT Cells.
    Front Immunol. 2015 Feb 04;6:37 PMID: 25699053
  184. Interleukin-17 promotes angiogenesis and tumor growth.
    Blood. 2003 Apr 1;101(7):2620-7 PMID: 12411307
  185. PI3Kγ is a molecular switch that controls immune suppression.
    Nature. 2016 Nov 17;539(7629):437-442 PMID: 27642729
  186. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
    Sci Transl Med. 2015 Mar 25;7(280):280sr1 PMID: 25810313
  187. Friend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development.
    Trends Immunol. 2017 Jan;38(1):29-38 PMID: 27810463
  188. The biology of human natural killer-cell subsets.
    Trends Immunol. 2001 Nov;22(11):633-40 PMID: 11698225
  189. RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers.
    Cancer Res. 2017 Mar 1;77(5):1083-1096 PMID: 28082403
  190. Molecular control of activation and priming in macrophages.
    Nat Immunol. 2016 Jan;17(1):26-33 PMID: 26681459
  191. Innate lymphoid cells--a proposal for uniform nomenclature.
    Nat Rev Immunol. 2013 Feb;13(2):145-9 PMID: 23348417
  192. State-of-the-art of regulatory dendritic cells in cancer.
    Pharmacol Ther. 2016 Aug;164:97-104 PMID: 27118338
  193. Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients: possible biological-clinical significance.
    PLoS One. 2014 Jun 10;9(6):e99512 PMID: 24915568
  194. Reflections on immunological nomenclature: in praise of imperfection.
    Nat Immunol. 2016 Mar;17(3):215-6 PMID: 26882248
  195. Aspirin and colorectal cancer: the promise of precision chemoprevention.
    Nat Rev Cancer. 2016 Mar;16(3):173-86 PMID: 26868177
  196. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling.
    J Biol Chem. 2012 Jun 1;287(23):19574-84 PMID: 22528488
  197. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma.
    Biochem Biophys Res Commun. 2011 Apr 8;407(2):348-54 PMID: 21396350
  198. Regulation of human NK-cell cytokine and chemokine production by target cell recognition.
    Blood. 2010 Mar 18;115(11):2167-76 PMID: 19965656
  199. Neuropilin-1 Is Expressed on Lymphoid Tissue Residing LTi-like Group 3 Innate Lymphoid Cells and Associated with Ectopic Lymphoid Aggregates.
    Cell Rep. 2017 Feb 14;18(7):1761-1773 PMID: 28199847
  200. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.
    Int J Cancer. 2015 Mar 15;136(6):E534-44 PMID: 25196138
  201. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.
    Med Oncol. 2015 Feb;32(2):352 PMID: 25572805
  202. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
    Cancer Immunol Res. 2016 Oct;4(10 ):858-868 PMID: 27549123
  203. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
    Cell Rep. 2015 Apr 28;11(4):577-91 PMID: 25892230
  204. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice.
    PLoS One. 2011 Apr 29;6(4):e19495 PMID: 21559338
  205. Anticancer effects of the microbiome and its products.
    Nat Rev Microbiol. 2017 Aug;15(8):465-478 PMID: 28529325
  206. VEGF as a mediator of tumor-associated immunodeficiency.
    Immunol Res. 2001;23(2-3):263-72 PMID: 11444391
  207. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
    N Engl J Med. 2010 Mar 11;362(10):875-85 PMID: 20220182
  208. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.
    Cell. 2000 Oct 27;103(3):481-90 PMID: 11081634
  209. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.
    Cancer Cell. 2011 Apr 12;19(4):512-26 PMID: 21481792
  210. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation.
    Sci Transl Med. 2013 Jan 30;5(170):170ra16 PMID: 23363980
  211. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors.
    Cancers (Basel). 2012 Sep;4(3):618-57 PMID: 22946011
  212. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions.
    Cancer Metastasis Rev. 2008 Mar;27(1):31-40 PMID: 18087678
  213. Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
    Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1809-14 PMID: 25624476
  214. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
    FEBS J. 2018 Feb;285(4):717-733 PMID: 28985035
  215. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
    FASEB J. 2006 Apr;20(6):621-30 PMID: 16581970
  216. Dendritic Cells and Cancer Immunity.
    Trends Immunol. 2016 Dec;37(12 ):855-865 PMID: 27793569
  217. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity.
    Nat Immunol. 2011 May 29;12 (7):631-8 PMID: 21623379
  218. Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention.
    Curr Drug Targets. 2011 Dec;12(13):1909-24 PMID: 21158708
  219. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Int J Cancer. 2012 Aug 1;131(3):E227-35 PMID: 22174092
  220. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model.
    J Exp Med. 2013 May 6;210(5):917-31 PMID: 23589566
  221. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
    Sci Rep. 2017 Mar 09;7:44123 PMID: 28276530
  222. Estimates of benefits and harms of prophylactic use of aspirin in the general population.
    Ann Oncol. 2015 Jan;26(1):47-57 PMID: 25096604
  223. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
    Int J Cancer. 2014 Apr 1;134(7):1669-82 PMID: 24105680
  224. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
    J Clin Oncol. 2009 Oct 1;27(28):4709-17 PMID: 19720929
  225. Myeloid-Derived Suppressor Cells.
    Cancer Immunol Res. 2017 Jan;5(1):3-8 PMID: 28052991
  226. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.
    Nat Med. 2014 Dec;20(12 ):1464-71 PMID: 25362254
  227. M-CSF from Cancer Cells Induces Fatty Acid Synthase and PPARβ/δ Activation in Tumor Myeloid Cells, Leading to Tumor Progression.
    Cell Rep. 2015 Mar 4;:null PMID: 25753425
  228. Cancer and the microbiota.
    Science. 2015 Apr 3;348(6230):80-6 PMID: 25838377
  229. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation.
    Immunity. 2012 Mar 23;36(3):451-63 PMID: 22425247
  230. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis.
    Immunity. 2013 Aug 22;39(2):357-71 PMID: 23954132
  231. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.
    Blood. 2006 Oct 15;108(8):2655-61 PMID: 16763205
  232. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
    Lancet Oncol. 2015 Aug;16(8):949-56 PMID: 26179200
  233. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  234. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients.
    Int J Oncol. 2009 Jul;35(1):115-20 PMID: 19513558
  235. Trabectedin: A drug from the sea that strikes tumor-associated macrophages.
    Oncoimmunology. 2013 Jun 1;2(6):e24614 PMID: 23894721
  236. Macrophage diversity enhances tumor progression and metastasis.
    Cell. 2010 Apr 2;141(1):39-51 PMID: 20371344
  237. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer.
    Int J Cancer. 2016 Jul 15;139(2):446-56 PMID: 26939802
  238. Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer.
    Curr Med Chem. 2017 Sep 20;:null PMID: 28933290
  239. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
    J Immunol. 2005 Nov 1;175(9):6177-89 PMID: 16237115
  240. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
    Ann Oncol. 2016 Aug;27(8):1482-92 PMID: 27069014
  241. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
    Cancer Res. 2007 Oct 1;67(19):9417-24 PMID: 17909051
  242. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.
    Nat Med. 2004 Sep;10(9):950-8 PMID: 15334073
  243. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
    Sci Transl Med. 2017 Apr 12;9(385):null PMID: 28404865
  244. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
    Mol Cancer Ther. 2008 Sep;7(9):2692-702 PMID: 18790751
  245. Bevacizumab plus ipilimumab in patients with metastatic melanoma.
    Cancer Immunol Res. 2014 Jul;2(7):632-42 PMID: 24838938
  246. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
    Nat Rev Clin Oncol. 2011 Mar 01;8(4):210-21 PMID: 21364524
  247. Innate Lymphoid Cells in Cancer.
    Cancer Immunol Res. 2015 Oct;3(10):1109-14 PMID: 26438443
  248. Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis.
    Curr Opin Immunol. 2017 Apr;45:8-15 PMID: 28088061
  249. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer.
    Immunity. 2014 May 15;40(5):785-800 PMID: 24816404
  250. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.
    J Immunol. 2010 Mar 1;184(5):2281-8 PMID: 20118280
  251. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression.
    Angiogenesis. 2012 Sep;15(3):391-407 PMID: 22476930
  252. Features of Memory-Like and PD-1(+) Human NK Cell Subsets.
    Front Immunol. 2016 Sep 14;7:351 PMID: 27683578
  253. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.
    Nature. 2010 Apr 29;464(7293):1371-5 PMID: 20393462
  254. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease.
    J Exp Med. 2011 Jun 6;208(6):1127-33 PMID: 21576383
  255. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.
    Science. 2010 May 7;328(5979):749-52 PMID: 20339029
  256. Microenvironmental regulation of tumour angiogenesis.
    Nat Rev Cancer. 2017 Aug;17 (8):457-474 PMID: 28706266
  257. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation.
    FASEB J. 2002 Feb;16(2):267-9 PMID: 11772950
  258. Natural killer (NK) cells from killers to regulators: distinct features between peripheral blood and decidual NK cells.
    Am J Reprod Immunol. 2007 Sep;58(3):280-8 PMID: 17681044
  259. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation.
    Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):728-32 PMID: 21187373
  260. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment.
    Neoplasia. 2014 Oct 23;16(10 ):771-88 PMID: 25379015
  261. Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma.
    J Invest Dermatol. 2017 Aug;137(8):1740-1748 PMID: 28433543
Article Info
Journal
Frontiers in immunology
Abbr.
Front Immunol
ISSN
1664-3224
DOI
10.3389/fimmu.2018.00527
Published
2018-00-00
Epub
2018-00-05
Pages
527
Language
English
Region
Switzerland
NLM ID
101560960
PMCID
PMC5895776
Subset
IM
External Links
PubMed source DOI: 10.3389/fimmu.2018.00527 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2